Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 DS-7830a safety, pharmacokinetics, and food-effect study in healthy Japanese adults
jRCT2051230152Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DS-7830a in major depressive disorder (MDD) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Adverse events and safety assessments and Plasma and urine pharmacokinetics of DS-7830a. Started Dec 2023; status: completed.
02
Drugs
DS-7830a
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2051230152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230152.